Nonalcoholic Steatohepatitis: Involvement of the Telomerase and Proinflammatory Mediators

Overview

Journal Biomed Res Int

Publisher Wiley

Specialties Biomedical Engineering
Biotechnology
General Medicine

Date 2015 Aug 15

PMID 26273651

Citations 8

Authors

Rim Serhal

George Hilal

George Boutros

Joseph Sidaoui

Layal Wardi

Salah Ezzeddine

Nada Alaaeddine

Affiliations

Soon will be listed here.

Abstract

Nonalcoholic steatohepatitis or NASH is an excessive accumulation of fat in hepatocytes accompanied by inflammation and hepatic injury. Proinflammatory molecules such as IL-17, CCL20, S100A8, S100A9, and S100A8/A9 have been shown to be implicated in many types of cancer. Telomerase activity has been found to be associated with chronic inflammation and cancer. NASH can progress to fibrosis then cirrhosis and finally to hepatocellular carcinoma (HCC). Our objective is to try to find a relation between inflammation and the progression of NASH into HCC. We found that there was a significant elevation in the telomerase activity, detected by real-time PCR, between NASH and fibrotic NASH in the liver biopsies of patients. The expression of S100A8, S100A9, S100A8/A9, CCL20, and IL-17, detected by ELISA, is significantly increased in NASH patients with fibrosis in comparison with controls. But, in NASH patients, S100A9, S100A8/A9, and IL-17 only are significantly elevated in comparison with controls. The same, on the mRNA level, expression of IL-17, detected by RT-PCR, is significantly elevated in NASH patients in comparison with controls. Therefore, there is a direct link between the expression of IL-17, CCL20, telomerase, S100A8, and S100A9 in the fibrotic condition and the progression towards cancer.

Citing Articles

Neutrophil-secreted S100A8/A9 participates in fatty liver injury and fibrosis by promoting myofibroblast migration.

Chang N, Liu Y, Li W, Ma Y, Zhou X, Zhao X J Mol Med (Berl). 2024; 102(9):1117-1133.

PMID: 38995368 DOI: 10.1007/s00109-024-02469-x.

Shared Genes and Molecular Mechanisms between Nonalcoholic Fatty Liver Disease and Hepatocellular Carcinoma Established by WGCNA Analysis.

He J, Zhang X, Chen X, Xu Z, Chen X, Xu J Glob Med Genet. 2023; 10(3):144-158.

PMID: 37501756 PMC: 10370469. DOI: 10.1055/s-0043-1768957.

Overview of Cellular and Soluble Mediators in Systemic Inflammation Associated with Non-Alcoholic Fatty Liver Disease.

Marques P, Francisco V, Martinez-Arenas L, Carvalho-Gomes A, Domingo E, Piqueras L Int J Mol Sci. 2023; 24(3).

PMID: 36768637 PMC: 9916753. DOI: 10.3390/ijms24032313.

Plasma Calprotectin Levels Associate with Suspected Metabolic-Associated Fatty Liver Disease and All-Cause Mortality in the General Population.

Bourgonje A, van den Berg E, Kieneker L, Nilsen T, Hidden C, Bakker S Int J Mol Sci. 2022; 23(24).

PMID: 36555350 PMC: 9778771. DOI: 10.3390/ijms232415708.

Role of Neutrophils in the Pathogenesis of Nonalcoholic Steatohepatitis.

Hwang S, Yun H, Moon S, Cho Y, Gao B Front Endocrinol (Lausanne). 2021; 12:751802.

PMID: 34707573 PMC: 8542869. DOI: 10.3389/fendo.2021.751802.

References

Feingold K, Soued M, Grunfeld C . Tumor necrosis factor stimulates DNA synthesis in the liver of intact rats. Biochem Biophys Res Commun. 1988; 153(2):576-82. DOI: 10.1016/s0006-291x(88)81134-3. View

Zwadlo G, Bruggen J, Gerhards G, Schlegel R, Sorg C . Two calcium-binding proteins associated with specific stages of myeloid cell differentiation are expressed by subsets of macrophages in inflammatory tissues. Clin Exp Immunol. 1988; 72(3):510-5. PMC: 1541584. View

Akerman P, Cote P, Yang S, McClain C, Nelson S, Bagby G . Antibodies to tumor necrosis factor-alpha inhibit liver regeneration after partial hepatectomy. Am J Physiol. 1992; 263(4 Pt 1):G579-85. DOI: 10.1152/ajpgi.1992.263.4.G579. View

Tracey K, Cerami A . Tumor necrosis factor, other cytokines and disease. Annu Rev Cell Biol. 1993; 9:317-43. DOI: 10.1146/annurev.cb.09.110193.001533. View

Hotamisligil G, Arner P, Caro J, Atkinson R, Spiegelman B . Increased adipose tissue expression of tumor necrosis factor-alpha in human obesity and insulin resistance. J Clin Invest. 1995; 95(5):2409-15. PMC: 295872. DOI: 10.1172/JCI117936. View

Chadeneau C, Hay K, Hirte H, Gallinger S, Bacchetti S . Telomerase activity associated with acquisition of malignancy in human colorectal cancer. Cancer Res. 1995; 55(12):2533-6. View

Tahara H, Nakanishi T, Kitamoto M, Nakashio R, Shay J, Tahara E . Telomerase activity in human liver tissues: comparison between chronic liver disease and hepatocellular carcinomas. Cancer Res. 1995; 55(13):2734-6. View

Hiyama E, Yokoyama T, Tatsumoto N, Hiyama K, Imamura Y, Murakami Y . Telomerase activity in gastric cancer. Cancer Res. 1995; 55(15):3258-62. View

Weng N, Levine B, June C, Hodes R . Regulated expression of telomerase activity in human T lymphocyte development and activation. J Exp Med. 1996; 183(6):2471-9. PMC: 2192611. DOI: 10.1084/jem.183.6.2471. View

10.

Shay J, Wright W . Telomerase activity in human cancer. Curr Opin Oncol. 1996; 8(1):66-71. DOI: 10.1097/00001622-199601000-00012. View

11.

Cressman D, Greenbaum L, DeAngelis R, Ciliberto G, Furth E, Poli V . Liver failure and defective hepatocyte regeneration in interleukin-6-deficient mice. Science. 1996; 274(5291):1379-83. DOI: 10.1126/science.274.5291.1379. View

12.

Kojima H, Yokosuka O, Imazeki F, Saisho H, Omata M . Telomerase activity and telomere length in hepatocellular carcinoma and chronic liver disease. Gastroenterology. 1997; 112(2):493-500. DOI: 10.1053/gast.1997.v112.pm9024303. View

13.

Shay J, Bacchetti S . A survey of telomerase activity in human cancer. Eur J Cancer. 1997; 33(5):787-91. DOI: 10.1016/S0959-8049(97)00062-2. View

14.

Bogumil T, Rieckmann P, Kubuschok B, FELGENHAUER K, Bruck W . Serum levels of macrophage-derived protein MRP-8/14 are elevated in active multiple sclerosis. Neurosci Lett. 1998; 247(2-3):195-7. DOI: 10.1016/s0304-3940(98)00263-8. View

15.

Tahara H, Kuniyasu H, Yokozaki H, Yasui W, Shay J, Ide T . Telomerase activity in preneoplastic and neoplastic gastric and colorectal lesions. Clin Cancer Res. 1995; 1(11):1245-51. View

16.

Stulik J, Osterreicher J, Koupilova K, Knizek , Macela A, Bures J . The analysis of S100A9 and S100A8 expression in matched sets of macroscopically normal colon mucosa and colorectal carcinoma: the S100A9 and S100A8 positive cells underlie and invade tumor mass. Electrophoresis. 1999; 20(4-5):1047-54. DOI: 10.1002/(SICI)1522-2683(19990101)20:4/5<1047::AID-ELPS1047>3.0.CO;2-E. View

17.

Matteoni C, Younossi Z, Gramlich T, Boparai N, Liu Y, McCullough A . Nonalcoholic fatty liver disease: a spectrum of clinical and pathological severity. Gastroenterology. 1999; 116(6):1413-9. DOI: 10.1016/s0016-5085(99)70506-8. View

18.

Petersen S, Schluns K, Gellert K, Dietel M, Petersen I . Chromosomal alterations in the clonal evolution to the metastatic stage of squamous cell carcinomas of the lung. Br J Cancer. 2000; 82(1):65-73. PMC: 2363206. DOI: 10.1054/bjoc.1999.0878. View

19.

Balkwill F, Mantovani A . Inflammation and cancer: back to Virchow?. Lancet. 2001; 357(9255):539-45. DOI: 10.1016/S0140-6736(00)04046-0. View

20.

Knosel T, Petersen S, Schwabe H, Schluns K, Stein U, Schlag P . Incidence of chromosomal imbalances in advanced colorectal carcinomas and their metastases. Virchows Arch. 2002; 440(2):187-94. DOI: 10.1007/s004280100493. View